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Background: Haemophilia is a rare hereditary haemorrhagic disease that requires regular intravenous injections of
clotting factor (CF) concentrates. This study sought to estimate the health and economic burden of haemophilia in
Belgium. This is the first study of its type to be conducted, and reflects the Belgian authorities’ growing interest for
haemophilia as part of their priority planning for rare and chronic diseases.
Methods: A probabilistic model was developed in order to estimate the lifetime haemophilia burden for the 2011
birth-year Belgian cohort. The health burden was initially expressed in terms of disability-adjusted life years (DALYs),
the number of healthy life years lost due to living with disability and dying prematurely. An incidence perspective
was used in line with World Health Organization recommendations. The economic burden calculated from direct
and indirect haemophilia-related costs was expressed in euros. Data were drawn from the literature if none were
available from federal institutions or health insurance. Disability weights for DALY calculation were derived using
generic quality-of-life tools such as SF-6D from the SF-36 (36-item Short-Form Health Survey; for adults) and KINDL
(generic quality-of-life instrument; for children) compared to population norms. Analyses were stratified according
to haemophilia type and severity.
Results: In Belgium, haemophilia resulted in 145 undiscounted and unweighted DALYs in total (95% credible interval
[CrI] = 90-222), which represents an average of 11 DALYs per incident case with haemophilia (95% CrI = 8-15) during his
life, varying according to haemophilia severity (17 DALYs for severe haemophilia, 12 DALYs for moderate, and 4 DALYs
for mild). Mean total lifetime costs reached €7.8 million per people with haemophilia, 94.3% being direct costs and
5.7% indirect costs. Clotting factors accounted for 82.5% of direct costs.
Conclusions: Haemophilia represents both an economic and health burden, especially regarding individual health on
an individual patient level. Initiatives to counteract this burden should be clearly identified and given full support, as
this burden is likely to increase in the future, especially from an economic perspective. Our study may also contribute
towards a better global evaluation of haemophilia in the future.
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Haemophilia A and B are rare X-linked haemorrhagic
disorders, caused by a lack of circulating clotting factor
VIII (FVIII) or factor IX (FIX), respectively, in blood. Men
are affected by the disease, while women are carriers.
Haemophilia severity, which depends on circulating clotting
factor levels in the blood, is defined as follows: severe
(<1 IU/dL), moderate (1–5 IU/dL) or mild (6–40 IU/dL)
[1]. If untreated, the bleeding tendency in haemophiliacs
may induce spontaneous bleedings leading to premature
death. However, treatments exist today that allow
many haemophiliacs to benefit from a close-to-normal
life expectancy, with the exception of a certain number of
severe haemophiliacs [2].
Before the 1990s, standard treatment for people with
haemophilia (PWH) consisted of infusions of human
plasma-derived clotting factor products. In the early
1980s, however, the emerging human immunodeficiency
virus (HIV) and hepatitis C epidemics had a devastating
impact on PWHs treated with this type of human
plasma product. The introduction of heat-treated
concentrates in 1985 diminished the risk of HIV and
hepatitis C infections [3], while the first recombinant
clotting factor products (in 1992 for FVIII and 1997
for FIX) resulted in the eradication of haematogenous HIV
and hepatitis C infections. Another major complication of
haemophilia includes recurrent spontaneous bleedings in
joints and muscles, which can lead to haemophilic
arthropathies in the long term, with severe impairments,
activity limitation, and thus productivity loss [4,5]. The
development of inhibitors to the clotting factor, resulting
in partial or complete lack of FVIII or FIX efficiency, is
another issue [4]. All these complications can seriously
impair the patients’ quality of life, with potential implica-
tions for employment, productivity, and patient psycho-
logical well-being [6,7]. In the past, untreated PWHs, and
particularly those with severe disease, tended to die earlier
than the general male population, with a life expectancy
below 30 years in 1960, and then below 60 years in
1980. Since the 1990s, the development of virus inactivation
techniques for preparing plasma-derived concentrates, as
well as recombinant concentrates, have improved PWH lifeTable 1 Distributions used to model the 2011 birth-year Belg
Parameter Distribution
Incidence Uniform (min = 1/
Number of haemophilia A, haemophilia B cases Dirichlet ({941, 212
Number of severe, moderate, mild haemophilia A cases Dirichlet ({440.4, 1
Number of severe, moderate, mild haemophilia B cases Dirichlet({63.6, 63.6
Standardized mortality rate Beta-PERT (min = 0
*The estimated number of severe, moderate and mild haemophilia cases was calcu
and 2011 from the Belgian Haemophilia Association data; Dirichlet: Dirichlet distribuexpectancy, so much so that it now approaches male life
expectancy in the general population of high- and middle-
income countries [8]. As a consequence, haemophilia
prevalence has been increasing over recent years.
While appropriate haemophilia management is essential
to reduce, or better prevent long-term implications, it
considerably increases costs for PWH and the rest of
society [4]. One appropriate management option consists
of prophylactic treatment administration, given one to
three times a week.
To our knowledge, the haemophilia health and economic
burden in Belgium has not yet been assessed. This study
pursued two principal objectives: 1) to estimate the
health burden of haemophilia in Belgium by using the
disability-adjusted life year (DALY) approach [9]; 2)
to assess the economic burden by calculating both
direct and indirect costs. Our study was in line with
the growing interest of authorities in rare and chronic
diseases, such as haemophilia, with respect to national
management strategies in Europe [10].
Methods
Birth cohort
We estimated the lifetime burden of haemophilia for the
2011 birth-year Belgian cohort. To this end, we simulated
the number of new-born males with haemophilia in 2011,
taking into account the number of male births in 2011
(67,149) along with a haemophilia incidence ranging
uniformly from 1/5500 to 1/4500 new-born males
[11-14]. The proportions of severe, moderate and
mild haemophilia A and B cases were modelled using
Belgian Haemophilia Association data (Table 1). For
severe haemophiliacs, we modelled the excess mortality
compared to the general 2011 Belgian mortality rates,
using the haemophilia standardized mortality rates
provided by Plug et al. (2006; Table 1) [15]. For moderate
and mild haemophiliacs, we assumed that there was no
haemophilia-related mortality [16]. To allow for inter-
national comparisons, we modelled the life expectancy of
surviving patients using the Coale-Demeny West model
life table, displaying a male life expectancy at birth of
80 years [17]. To account for parameter uncertainty, weian cohort of haemophilia patients
Reference
5500, max = 1/4500) Rosendaal and Briet [11]
}) Belgian Haemophilia Association (year 2011)
80.7, 319.9}) Belgian Haemophilia Association
(years 2006–2011)*
, 84.8}) Belgian Haemophilia Association
(years 2006–2011)*
.8, mode = 1.4, max = 2.4) Plug et al. [15]
lated using the mean number of new cases with haemophilia between 2006
tion; Beta-PERT: Beta-PERT distribution.
Table 2 Disability weights used for adults and children with










*The most likely value for the disability weights was estimated using the
KINDL questionnaire for children from the scientific literature [23] compared to
KINDL population norms [24] and the SF-6D generated from the SF-36
quality-of-life questionnaire filled out by 71 PWHs in Belgium [25] compared
to the SF-6D population norms [26].
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drawn values of the various input distributions. All
simulations and calculations were conducted using
the R Software version 2.15.2 [18].
Disease burden
Disability-adjusted life years (DALYs), which represent
the number of healthy life years lost due to haemophilia,
are calculated by adding the adjusted number of years
lived with disability (YLDs) to the number of years of life
lost due to premature mortality (YLLs). In their simplest
form, the formulae for YLDs and YLLs are [19]:
YLD ¼ number of incident cases  duration of the
disease  disability weight
YLL ¼ number of deaths  standard life expectancy
at age of death
Disability weights (DW) are a crucial factor in YLD
calculation, as they allow for adjustment of the number
of years lived with disability and for comparison with the
number of life years lost due to premature mortality
[20]. The haemophilia DW indicates to which extent
haemophilia reduces the patient’s physical capacity,
ranging from zero (full health) to one (worst possible
health state). As DWs are dependent on social choices,
several sets of DWs have been developed, such as the
Global Burden of Disease (GBD) DWs [21] and the
Dutch Severity Weights [22].
Since no haemophilia-specific DWs were available
either in the Global Burden of Disease list nor the Dutch
Disability Weights Group, data from a generic-based
questionnaire for both adults and children were used. As
no quality-of-life evaluation using generic assessments in
haemophiliac children was available in Belgium, we took
the DWs estimated from the mean KINDL score from
KINDL questionnaire for children with haemophilia
from the scientific literature [23] minus the mean
KINDL score for boys from the normal population
(population norms) for each specific age groups [24].
For adults, the DW estimation was based on the results
of the SF-6D scores generated from the SF-36 quality-
of-life questionnaire filled out by 71 PWHs in Belgium
[25] minus the mean SF-6D score for males in the
general population (population norms) and for each age
groups [26]. The DWs chosen for both children and
adults are shown in Table 2.
Standard DALY calculation requires taking into
account two other social preference criteria, namely age
weighting and time discounting. Age weighting gives a
higher significance to the period of 9 to 54 years of age,
as these years are generally regarded as being of greater
social value [27,28]. However, the limited empirical
evidence of such an approach along with the resultinginequality between ages have attracted criticism. Time
discounting reduces the impact of years lived in the fu-
ture, generally at a rate of 3%. This strategy, which is in
line with economic assessments, prevents policy-makers
from investing in potential future eradication programs
rather than control programs that are possible right now,
yet perhaps less effective, which is known as the research
paradox. Time discounting has also received criticism,
mainly on the grounds of inequality as explained
above. Given this controversy, we decided to report
both undiscounted and unweighted DALYs as our
base case scenario. However, to allow for comparison
with other studies, we conducted scenario analyses,
with DALYs calculated based on a 3% time discount
rate, both with and without age weighting as well as
1.5% time discount rate without age weighting.
Cost analysis
Cost estimations were performed using data from the
National Alliance of Christian Mutualities (NACM)
database, which is the largest Belgian sickness fund,
covering approximately 42% of the population. All
data extractions and analyses were conducted at the
NACM medical management department under the
supervision of a medical advisor. In Belgium, sickness
insurance is legally compulsory. As no medical diagnosis
was reported in the database, our cost calculations
included all male patients who had at least one specific
haemophilia medication injection in 2011, such as
clotting factor VIII (ATC code B02BD02), clotting
factor IX (ATC code B02BD04), nonacog alfa (BeneFIX)
(ATC code B02BD09), factor VIII inhibitor bypassing
activity (FEIBA) (ATC code B02BD03) and activated
eptacog alfa (NovoSeven) (ATC code B02BD08), and
who were still alive on December 31, 2011. For the
patients selected between January 1, 2011 and December
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patient costs were calculated and used as references in the
cost calculations (see Additional files 1 and 2). In addition,
the exact total 2011 costs of all above-mentioned specific
haemophilia medications mentioned above was provided
by the National Institute for Health Care and Disability
Insurance. Using the NACM database, the following costs
were estimated: number and mean cost of visits to general
practitioner (GP), specialist, physiotherapist and dentist;
number of days and average daily cost of hospitalisation
hospital stay and day hospitalisation; average costs of
other expenses. All these costs were considered direct
costs. Calculated indirect costs included transport costs to
and from the doctor’s office and hospital, as well as
absence from work due to these appointments and
hospitalisations. Transport costs were estimated based
on a travel distance ranging uniformly from 0 to 200 km
with a cost of €0.30 per km travelled; the daily cost of
absence from work was assumed to equal the average
gross daily income. The cost of absence from work due to
invalidity or premature death was assessed for patients
aged 20–64 by means of a friction-cost method [29]. Using
this method, costs were only considered for the period
required to replace a sick or deceased worker. In Belgium,
however, precise data on the length of this so-called
friction period was unavailable. This uncertainty was
accounted for by modelling the friction as a uniform
distribution ranging from 2 to 6 months [30]. The
distributions used in the cost assessment model for
the 2011 birth-year Belgian cohort of haemophilia patients
are shown in Additional files 1 and 2. In the results
section, we have estimated the lifetime costs for new
incident haemophilia cases born in 2011 applying no
time discounting and 3.5% time discounting [31].Table 3 Number of estimated new cases, overall and per case
Estimated number of new cases
in 2011 (95% CrI)












95% CrI: 95% credible interval.
Number of estimated new haemophilia cases, overall lifetime haemophilia burden a
Belgium in 2011.Sensitivity analyses
Probabilistic sensitivity analyses were conducted in order
to assess the sensitivity of DALYs and cost estimates as
affected by the uncertainty in the input parameters.
Spearman’s rank-order correlations were employed to
assess the association between the random deviates from
the input parameters and the simulated DALY and cost
estimates. The correlation coefficient for each input
parameter was then taken as a measure of model
sensitivity, with values higher than zero indicating
positive associations and values lower than zero indicating
negative associations.
Results
Disability-adjusted life years (DALY)
For the 2011 Belgian population, haemophilia was estimated
to be the cause of a total of 145 (95% credible interval
[95% CrI]: 90–222) healthy life years lost (DALYs),
with 119 (95% CrI: 81–171) being due to years lived
with disability (YLDs) and 26 (95% CrI: 0–64) years
lost due to premature mortality (YLLs) (Table 3). DALYs
were higher for haemophilia A (123 DALYs) than for
haemophilia B patients (22 DALYs), given the higher
haemophilia A’s incidence than haemophilia B. If we
consider haemophilia severity, the mean number of
DALYs per case was highest in severe haemophiliacs, with
a mean of 17 DALYs per severe haemophiliac, whereas
moderate haemophiliac cases had a mean of 12 DALYs,
and mild haemophiliacs a mean of 4 DALYs (Table 3).
The scenario analyses assessing the impact of alternative
social preference functions on overall and individual
lifetime haemophilia burden per haemophilia type for the
2011 birth-year Belgian cohort are provided in Table 4 in
order to be able to compare the results obtained withlifetime burden (Belgium, 2011)
DALY (95% CrI) DALY per case (95% CrI)
145 (90–222) 11 (8–15)
98 (43–175) 17 (13–20)
29 (27–31) 12 (5–25)
18 (17–20) 4 (2–9)
123 (74–193) 11 (8–16)
86 (37–156) 17 (13–20)
22 (20–23) 12 (5–28)
15 (14–17) 5 (2–10)
22 (12–42) 10 (5–18)
12 (2–32) 17 (13–20)
7 (6–8) 16 (4–55)
3 (2–3) 4 (1–13)
nd lifetime haemophilia burden per case per haemophilia type and severity in
Table 4 Scenario analyses on lifetime haemophilia burden for 2011 in Belgium






DALY DALY per case DALY DALY per case DALY DALY per case
(95% CrI) (95% CrI) (95% CrI) (95% CrI) (95% CrI) (95% CrI)
Haemophilia (total) 72 (46–108) 5 (4–8) 40 (26–58) 3 (2–4) 47 (31–69) 4 (3–5)
Severe 47 (21–82) 8 (7–9) 25 (11–43) 4 (4–5) 30 (14–51) 5 (5–5)
Moderate 15 (14–16) 6 (3–13) 8 (8–9) 3 (2–7) 10 (9–11) 4 (2–9)
Mild 10 (9–11) 2 (1–5) 6 (6–7) 1 (1–3) 7 (7–8) 2 (1–4)
95% CrI: 95% credible interval.
Results of the scenario analyses assessing the impact of alternative social preference functions on overall and individual lifetime haemophilia burden per
haemophilia type for the 2011 birth-year Belgian cohort are shown.
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haemophilia resulted in 72 DALYs applying 1.5% time
discounting and no age weighting, 40 DALYs applying 3%
time discounting and no age weighting and 47 DALYs
applying 3% time discounting and age weighting.
Sensitivity analyses indicated results to be mostly
influenced by the uncertainty in the proportion of
severe haemophiliacs A, and then by the uncertainty in
standardized mortality rates and incidence (Figure 1A).
Cost estimation
The total lifetime costs were estimated at €97.4 million
(95% CrI: €47.1–158.1 million) for new incident haemophiliaFigure 1 Sensitivity analysis for DALY assessment (A) and cost estima
different from zero are presented in the figure. HA: haemophilia A; HB: haecases born in 2011 applying no time discounting, with
a mean lifetime cost of €7.8 million per new incident
haemophilia case (Table 5). The total lifetime costs,
discounted at an annual rate of 3.5%, were estimated at
€32.2 million, which is about one third of the undiscounted
estimate (Table 5). At almost €92 million, the direct costs
accounted for 94.3% of the total costs. Specific haemophilia
treatments alone accounted for 77.8% of the total and
82.5% of the direct costs, with €75.4 million for all
haemophiliacs (Table 6). Large differences were observed
between haemophilia A and B patients regarding treatment
costs, with costs for haemophilia A treatment being
approximately ten times higher than those for haemophiliation (B). Only parameters with a correlation coefficient significantly
mophilia B; GP: General practitioner.
Table 5 Estimates of 2011 indirect and direct costs due to haemophilia in Belgium
Scenario No time discounting 3.5% time discounting
Cost Mean total cost Mean cost per incident case Mean total cost Mean cost per incident case
(95% CrI) (€) (95% CrI) (€) (95% CrI) (€) (95% CrI) (€)
Total 97,336,761 7,826,097 32,201,550 2,598,176
(47,139,079–158,080,868) (3,770,640–12,700,923) (15,663,972–51,743,686) (1,242,147–4,192,128)
Direct 91,773,744 7,379,337 30,491,342 2,460,299
(44,416,357–148,640,854) (3,534,774–11,959,182) (14,846,997–48,928,191) (1,173,455–3,955,981)
Indirect 5,563,016 446,760 1,710,208 137,878
(1,657,623–12,092,403) (134,444–976,977) (544,059–3,592,225) (43,083–293,984)
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higher than haemophilia B incidence. The distributions
used in the cost assessment model for the 2011 birth-year
Belgian haemophilia patient cohort are shown in
Additional files 1 and 2.Table 6 Estimated costs for haemophilia in Belgium in 2011,
by category (in €)
Categories Mean cost (€) 95% credible interval (€)
Haemophilia treatment 75,446,373 37,224,222–120,744,110
Haemophilia A 69,021,625 33,046,471–110,694,830
Haemophilia B 6,424,748 2,443,720–12,437,337
GP visits 568,828 145,241–1,430,049
Consultation 214,643 81,459–424,020
Transport 354,184 14,568–1,068,605
Specialist visits 1,080,910 269,546–2,632,399
Consultation 441,227 152,963–904,770
Transport 639,684 27,504–1,830,506
Physiotherapist visits 2,024,912 316,369–5,751,834
Consultation 602,380 146,291–1,408,041
Transport 1,422,532 54,573–4,543,715






Work absence 779,316 211,534–1,755,167
Day hospitalization 4,395,306 707,454–12,810,868
Hospitalization 2,650,648 425,488–7,671,586
Transport 663,505 21,321–2,375,286
Work absence 1,081,153 183,381–3,046,125




GP: General Practitioner.The cost of health care professional consultations
(for GP, specialists, physiotherapists and dentists) repre-
sented only 1.6% of total direct costs, with physiotherapist-
consultation costs accounting for 41.8% of the total health
care visits costs (Table 6). Costs of specialist consultations
accounted for 30.6% of these health care visits costs, which
was followed by costs related to GP visits, with dentist visits
coming last.
The total direct costs for hospital stays and day hospitali-
sations represented 6.9% of the direct costs. These hospita-
lisations made up the majority of total indirect costs
(53.9%), due to transport and absence-from-work costs.
Sensitivity analyses for the cost assessment indicated
that the uncertainty in the total cost estimates was
mostly influenced by the uncertainty in incidence rate of
haemophilia and other National Institute for Health
Care and Disability Insurance (INAMI) costs for patients
over 20 years of age (Figure 1B).
Discussion
DALY calculations for haemophilia in Belgium indicated
145 years lost due to disability or premature death, with
a mean of 11 DALYs per incident case. The years lived
with disability (YLDs) were seen to have the highest
contribution to haemophilia-related DALYs, namely
83.4%, while the years of life lost due to premature
mortality (YLLs) were responsible for only 16.6%. This
result was not entirely unexpected, as haemophiliac life
expectancy closely resembles that of the general population,
on account of safe replacement therapies, with the
exception of severe haemophiliacs. Moreover, this
observation highlights haemophiliac patients’ poorer
quality of life compared to that of the general population,
although the gap is now closing between the two. In
addition, severe haemophiliacs contributed to approximately
two thirds of the total DALYs, underlining how far we still
have to go to improve severe haemophiliac’s quality-of-life
and premature mortality. However, as is a common
assumption for all rare diseases, the low total number of
haemophilia-related DALYs could lead to haemophilia being
viewed as a disease with little burden [32].
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to be conducted in either Belgium or the world. The
only published study evaluating evaluate the burden of
haemophilia through DALYs involved 19,920 U.S.
haemophiliac males, with a total of 107,346 DALYs
reported applying 3% time discounting and age weighting
[33]. YLL accounted for 12.1% of these DALYs, and YLD
for 87.8%. In our study, applying 3% time discounting and
age weighting to DALY calculations, YLL accounted for
5.5% of these DALYs, and YLD for 94.5%.
Cost analyses stressed the economic burden due to
haemophilia, with total lifetime costs of €97.3 million
(95% CrI: €47.1–158.1 million) for new incident 2011-born
haemophiliac cases, with a mean lifetime cost of €7.8 mil-
lion per incident case. Direct costs accounted for 94.3% of
the total costs, namely €91.8 million, with a high contribu-
tion of treatment-related costs (82.5%) to direct costs and a
relatively low contribution of hospitalisation-related costs
(6.8%) to direct costs. Large differences in treatment costs
were observed between the two types of haemophilia,
haemophilia B being five times less frequent than
haemophilia A and the proportion of severe haemophilia A
patients being higher than the proportion of severe haemo-
philia B patients in Belgium [1]. The annual cost of specific
haemophilia medication injection in 2011 was €65.6 million
for clotting factor VIII (ATC code B02BD02), €0.6 million
for clotting factor IX (ATC code B02BD04), €6.6 million for
nonacog alpha (BeneFIX) (ATC code B02BD09), €1.5
million for factor VIII inhibitor bypassing activity (FEIBA)
(ATC code B02BD03), and €6.7 million for activated
eptacog alpha (NovoSeven) (ATC code B02BD08). This
demonstrates the higher use of replacement therapy for
haemophilia A than haemophilia B. However, our study’s
total costs are not comparable with those of other studies
on account of the incidence approach we used, as well as
differences in health care systems (e.g., access to
health insurance) and haemophilic medication unit
prices between countries. Yet several studies evaluating
haemophilia direct costs revealed approximately 85% of
direct costs related to anti-haemophilic medication
[34-36], in line with the 82.5% found in our study.
A major limitation of our study was the lack of reliable
local disease data, as the exact number of haemophiliacs
and the distribution of severity types across Belgium were
not known and thus had to be estimated. This uncertainty
was reflected in the sensitivity analyses that indicated that
haemophilia incidence was a major parameter contributing
to the overall uncertainty. Furthermore, as there was only
scarce information on the number of patients developing
inhibitors, we were not able to perform precise health and
economic burden assessments for this patient population.
The total lifetime costs could be very different for patients
with inhibitors compared to those without. On the other
hand, it must be mentioned that cost estimates werecalculated using a representative Belgian database from the
largest national sickness fund. Lastly, we conducted
uncertainty analyses, propagating the uncertainty in the
input parameters to the final DALY or cost estimate.
In this study, the future health and economic burden of
haemophilia was predicted using the incidence approach.
To this end, we assumed that haemophilia incidence would
remain constant over time, which we consider justified
for this rare genetic disease. Yet the future burden of
haemophilia is likely to change with the development
of innovative treatments, such as long-acting clotting
agents or gene therapy, or the availability of Biosimilars
[1]. In addition, the introduction of these treatments will
likely impact future costs related to haemophilia.
The extensive use of effective prophylactic clotting factor
replacement therapies, especially in children and severe
haemophiliacs, has considerably pushed up treatment-
related costs in Belgium, with a total cost of 33 million euro
in 2002 up to 81 million euro in 2011 [37]. Although the
use of an effective prophylactic approach may thus seem
costly on the surface, several studies have shown that
prophylaxis minimises and prevents long-term haemophilia
complications, such as arthropathies, as well as increased
disability and earlier death. Moreover, early introduction of
prophylaxis may help to reduce the cost of inhibitor-related
costs [38]. Consequently, prophylaxis appears crucial im-
proving the health and economic consequences of haemo-
philia, ensuring a better quality of life for haemophiliacs
and hence a lower disease burden [1,39,40]. Given the
current economic downturn, individualised therapy, appro-
priate pharmacokinetic-dosing and/or tender processes may
help to reduce costs [41,42]. For recombinant products
similar prices have been maintained since 1991 and the
revision of this issue might help to support the treatment of
patients at a lower cost. In addition, increasing expensive
rare disease therapies could stimulate competition, poten-
tially leading to price competitiveness of such therapies. It
should also be noted that FVIII and FIX concentrates are
considered essential medicines by the World Health Organ-
isation (WHO) for both adults and children according
to the 17th WHO Essential Medicines List and the 3rd
WHO Essential Medicines List for Children [43].
In conclusion, although haemophilia has a minor impact
on the overall disease burden, the repercussions it has on
the individual patient remain substantial. Initiatives for
reducing this burden should be clearly identified and given
full support. To reduce haemophilia treatment costs, a
compromise must be made between the patient benefitting
from the treatment, for whom the treatment has to be
available and affordable, and the national authorities facing
budget constraints, as well as the pharmaceutical compan-
ies investing in research and development [44]. Finally, re-
search and development of new drugs in the haemophilia
field still needs to be further promoted.
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